Categories Earnings, Health Care

Regeneron Q1 profit falls 4%, misses estimates

Regeneron Pharmaceuticals (NASDAQ: REGN) reported a 4% decline in earnings for the first quarter of 2019 due to higher costs and expenses. The results missed analysts’ expectations. However, higher product sales drove total revenues higher by 13%.

Net income decreased 4% to $461 million and earnings fell by 4% to $3.99 per share. Adjusted earnings dropped by 5% to $4.45 per share.

Total revenues grew 13% to $1.71 billion. Higher sales from Eylea injection, which was administered into the eye to treat certain retinal diseases, drove net product sales higher by 12%. Libtayo, which was approved by the FDA to treat a type of skin cancer, had net product sales in the United States of $26.8 million in the first quarter of 2019.

Regeneron Pharmaceuticals (NASDAQ: REGN) reported earnings for the first quarter of 2019.

Looking ahead into the full year 2019, the company now expects unreimbursed R&D expenses of $1.855 billion to $2 billion and selling, general and administrative expenses of $1.690 billion to $1.795 billion. Capital expenditures are now anticipated to be $410 million to $475 million. The effective tax rate is now predicted to be 11% to 13%.

For the first quarter, revenues from Sanofi and Bayer collaboration jumped 20% year-over-year. The increase in Sanofi collaboration was due to the company’s share of lower losses of collaboration antibodies, primarily driven by higher net product sales of Dupixent. This was partly offset by a decrease in reimbursement of R&D costs under the Immuno-oncology Discovery and Development Agreement with Sanofi.

The change in Bayer collaboration revenue was due to a rise in net profits in connection with higher sales of Eylea outside the US. The company recognized its share of the profits, including a percentage of sales in Japan, from Eylea sales outside the US within Bayer collaboration revenue.

Image Courtesy: Regeneron / Facebook post

For the first quarter, R&D expenses increased by 29% principally due to additional costs incurred in connection with its earlier-stage pipeline, an increase in Libtayo development expenses, higher clinical manufacturing costs, and higher headcount and headcount-related costs.

Regeneron has twenty product candidates in clinical development, including five of the company’s U.S. Food and Drug Administration (FDA), approved products for which it is investigating additional indications. The company initiated phase 3 clinical study of Dupixent in chronic obstructive pulmonary disease (COPD).

Shares of Regeneron ended Monday’s regular session up 2.18% at $344.23 on the Nasdaq. The stock has risen over 18% in the past year while it has fallen over 15% in the past three months.


Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

INTU Earnings: Intuit Q3 2024 revenue and adj. profit top expectations

Intuit Inc. (NASDAQ: INTU) Thursday reported an increase in adjusted earnings and revenues for the third quarter of 2024. The results also exceeded analysts' estimates. At $6.74 billion, the Mountain

After blowout quarter, Nvidia (NVDA) looks set to continue riding the AI wave

Shares of NVIDIA Corporation (NASDAQ: NVDA) rallied this week after the semiconductor giant reported robust first-quarter numbers. Being a first mover in artificial intelligence chips, the company is spearheading the

Target Corp. (TGT): A brief look at the retailer’s performance in Q1 2024

Shares of Target Corporation (NYSE: TGT) rose over 1% on Thursday. The stock has dropped over 11% in the past one month. The company delivered mixed results for the first

Add Comment
Viewing Highlight